Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onapristone - Context Therapeutics

Drug Profile

Onapristone - Context Therapeutics

Alternative Names: Apristor; AR-18; IVV-1001; Onapristone - Arno Therapeutics; Onapristone extended-release; ZK 299; ZK 98299

Latest Information Update: 06 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Arno Therapeutics; Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Context Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Antiprogestogens; Dimethylamines; Gonanes; Small molecules
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
  • Discontinued Breast cancer; Endometriosis; Pregnancy; Uterine cancer

Most Recent Events

  • 01 Jul 2020 Adverse events data from preclinical trial in cancer released by Context Therapeutics
  • 01 Jul 2020 Adverse events data from a phase I/II trial in prostate cancer and another phase I/II trial in breast cancer, endometrial cancer and ovarian cancer released by Context Therapeutics
  • 01 Jul 2020 Context Therapeutics plans multiple phase II trials for ER+, PR+, HER2- breast cancer and PR+ endometrial cancers in 2020 (PO, Controlled release)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top